Is the Chinese name of AMG510 targeted drug sotoracib?

AMG510 is an anti-KRASG12C targeted drug undergoing clinical trials, and its research and development company Amgen gave it a code name. In the Chinese market, the candidate name of this drug is translated as Sotorasib, which is based on the naming convention of its chemical structure and development stage. Sotoraxib is an oral small molecule inhibitor that specifically binds to and inhibits the KRAS G12C mutation, a common causative genetic mutation in tumors such as non-small cell lung cancer.

KRAS is a key signaling protein that, when mutated in its G12C, may cause cells to continue growing and spreading without normal regulation. By blocking this abnormal signaling, sotoracib may provide a treatment option for patients with KRAS G12C-positive cancers. Early clinical data shows positive efficacy. Sotorasibu has also been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and is available in the United States, the European Union, Canada and other regions. It is also sold under the trade names of Lumakras and Lumykras.

The development of sotoracib represents an important breakthrough for targeting KRAS mutations, as the KRAS gene has long been considered difficult to target directly. As a new type of targeted drug, sotoracib has shown good efficacy and safety in clinical trials. Of course, when using any drug, you need to follow the doctor's instructions, and pay close attention to the body's reaction and possible side effects during the treatment process, so that the doctor can adjust the treatment strategy in time to ensure the best treatment effect.